Back to CYTKView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Heart Failure With Reduced Ejection Fraction
View Full LandscapeDrug Information
Target Indication
Heart Failure With Reduced Ejection Fraction
Clinical Trial
NCT02695420Last updated: 1/2/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Standard of CarePhase 3
Heart Failure
Omecamtiv MecarbilPhase 3
Heart Failure With Reduced Ejection Fraction
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)Phase 3
Obstructive Hypertrophic Cardiomyopathy (oHCM)
AficamtenPhase 3
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Phase 3
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts